Objectives-Microembolic signal detection by transcranial Doppler ultrasonography may be considered a surrogate for cerebral events during invasive cardiac procedures. However, the impact of the microembolic signal count during pulmonary vein isolation on the clinical outcome is not well evaluated. We investigated the effect of the microembolic signal count on the occurrence of new silent cerebral embolism measured by diffusion-weighted imaging (DWI)-magnetic resonance imaging (MRI), changes in neuropsychological testing, and the occurrence of clinical events during long-term follow-up after pulmonary vein isolation.
microembolization into brain-supplying arteries.
1,2 New silent cerebral embolism can be depicted on DWI-MRI in up to 50% of patients after left atrial catheter ablation and often involve the watershed region between the 3 large cerebral artery territories. 3, 4 Thus, there is considerable interest in biological markers for detecting subtle asymptomatic brain injury to increase the safety of cardiac procedures and not to rely on end point studies. [5] [6] [7] Microembolic signals imbedded in the Doppler spectrum derived from transcranial Doppler ultrasonography (US) are online markers of thromboembolic disease and are caused by an increase in acoustic impedance/backscatter of solid or gaseous particles over erythrocytes. The most convincing data have been shown to be the differentiation of high-and low-risk internal carotid artery stenosis and potency of single versus dual platelet inhibition in symptomatic high-grade internal carotid artery stenosis. 8 Microembolic signals on transcranial Doppler US have also been tested in cardiac disease (ie, atrial fibrillation) but also to compare the periprocedural stroke risk during invasive internal carotid artery stenting techniques or during coronary angiography. 9, 10 With respect to interventional cardiology, the microembolic signal count may be considered a surrogate for stroke risk during left atrial catheter ablation (ie, pulmonary vein isolation for atrial fibrillation). [11] [12] [13] [14] [15] [16] [17] [18] Interestingly, although an average of 1793 6 547 microembolic signals 11 were reported in a single ablation procedure, only a little data on correlation of microembolic signals and MRI-detected cerebral lesions or neuropsychological sequelae are available. 19 In this multicenter study, we investigated the correlation between an intraprocedural microembolic signal count and the occurrence of new DWI lesions, changes in the neuropsychological capability, and the occurrence of stroke/transient ischemic attack during long-term followup after left atrial catheter ablation for atrial fibrillation.
Materials and Methods

Study Design
This multicenter observational nonrandomized prospective trial was performed at 3 institutions, Universit€ atsklinikum Regensburg, Universit€ ares Herzzentrum Bad Krozingen, and Herz-und Gef€ ass-Klinik Bad Neustadt, between July 2011 and November 2012. Follow-up interviews to request information on cerebral events after completion of the study were performed by telephone in 2016 for all study patients. Ethics approval was obtained from the University of Regensburg (No. 11-101-0134) before the trial commenced, and the study was registered with an international trial registry in Freiburg, Germany (Deutsches Register Klinischer Studien, No. DRKS00003465). Informed written consent was obtained from all patients before inclusion in the study. The inclusion criterion was pulmonary vein isolation for atrial fibrillation. The main exclusion criteria were patient age younger than 18 and older than 80 years, chronic neurological disease, diagnosis of dementia, prior left atrial ablation, severe claustrophobia (for MRI investigation), and implanted cardiac devices (contraindicated for MRI). Oral anticoagulation therapy for at least 4 weeks before the procedure was required to minimize the risk of a left atrial thrombus. In patients receiving phenprocoumon, an international normalized ratio level between 2 and 3 before and after the ablation procedure was intended. During the study period, a new orally administered direct thrombin inhibitor (dabigatran etexilate, Pradaxa; Boehringer Ingelheim, Ingelheim, Germany) was approved for anticoagulation in patients with nonvalvular atrial fibrillation; patients taking this drug were regarded as having full anticoagulation. Patients taking warfarin were treated without discontinuation and bridging. In patients taking dabigatran, oral anticoagulation therapy was stopped 24 hours before the ablation procedure but also without bridging. After trans-septal puncture, all patients received intraprocedural heparin to achieve an activated clotting time of greater than 300 seconds when necessary. Activating clotting times were controlled every 30 minutes. All patients received transesophageal echocardiography to rule out the presence of a left atrial thrombus. Figure 1 depicts a flow chart of the study protocol. Methodical aspects, such as ablation techniques applied, microembolus detection by transcranial Doppler US (microembolic signals on transcranial Doppler US), DWI-MRI, and neuropsychological testing, have been described elsewhere 5, 20 and will be clarified in brief at this point.
Ablation Techniques
Three different standardized ablation techniques were used to achieve pulmonary vein isolation: (1) Irrigated radiofrequency (RF) ablation was performed with an irrigated-tip catheter (NaviStar Thermocool or SmartTouch; Biosense Webster, Diamond Bar, CA) and In general, a 28-mm balloon was used. Each pulmonary vein was frozen twice over 5 minutes in the best position for occlusion to achieve electrical isolation of all pulmonary veins. The end point of the procedure was the electrical isolation of all pulmonary veins.
Microembolus Detection Using
Transcranial Doppler US At all centers, microembolic signal transcranial Doppler US was performed during the ablation procedure with the same equipment (Doppler Box; DWL, Singen, Germany). A teaching session for this multicenter trial was held before study initiation. Continuous bilateral insonation in the middle cerebral artery territory was attempted with the patient in the supine position for cardiac intervention. In accordance with the international consensus recommendations, the sample gate was 8 mm, and the Doppler gain was reduced to show only faint Doppler spectra. 21 After sedation of the patient, we identified the best temporal bone window on both sides whenever possible and locked the transducer to the frame in this position. The gain was adjusted as low as possible with faint recognition of the Doppler spectrum. With the beginning of the cardiac procedure recording, the Doppler spectral signal was started. During the procedure, the cardiologist was unaware of the Doppler signals.
A blinded offline analysis of the recorded microembolic signal transcranial Doppler US data was performed in a single center by 2 different neurologists familiar with the technique according to standard criteria. 21 In previous studies, application of the implemented gaseous/ solid differentiation software with its detection algorithm was found to be ineffective, probably because of the magnitude and dense number of signals as well as frontend overload, among other factors. 8, [22] [23] [24] Thus, manual analysis of microembolic signals comprised listening to each signal and watching each signal on screen at the highest speed. Ratings were assigned without using a decibel threshold. Single countable microembolic signals were summed up to a total microembolic signal count. Definitely "solid" emboli were strictly unidirectional within the Doppler spectrum and had an acoustic impedance of greater than 8 dB over the baseline. Clearly "gaseous" emboli were characterized as large and high-intensity bidirectional signals exceeding the Doppler spectrum probably because of stimulated acoustic emission from bubble bursts by the incident US wave. 25 When signals did not meet the strict criteria for solid or gaseous emboli, they were classified as "equivocal." In addition, periods with a huge amount of microembolic signals of longer than 30 seconds were classified as thromboembolic showers.
Cerebral MRI Fluid-attenuated inversion recovery MRI, DWI-MRI, and apparent diffusion coefficient MRI studies using routine parameters were performed 1 day before as well as 1 day and 1 month after the ablation procedure to detect preexisting cerebral lesions and postablation silent cerebral embolisms. To detect postablation silent cerebral embolisms, we used a sensitive definition of silent cerebral embolism that does not require a positive indication on fluid-attenuated inversion recovery MRI studies. All follow-up examinations were performed by the same investigators and focused on the appearance of new lesions on DWI-MRI studies with an apparent diffusion coefficient signature confirming the presence of acute ischemic events.
Neuropsychological Testing
Neuropsychological testing was performed close in time to the MRI studies 1 day before and soon (1 day and 1 month) after the ablation procedure. Each patient's verbal working memory was measured by the Digit Span Test (forward and backward versions). The TrailMaking Test (parts A and B) was conducted to measure complex conceptual tracking, planning, and cognitive flexibility. Verbal fluency, an executive cognitive function, was measured by administering the Controlled Oral Word Association Test (letters B, F, and L) for phonemic fluency and the Regensburger Wortfl€ ussigkeitstest (animal and food categories) for semantic fluency. Visual and sustained attention was measured by the Ruff 2 & 7 test. With respect to the statistical analysis, raw scores were transformed into z scores (z 5 raw score-mean/standard deviation) for patient age and sex and, in the case of the Trail-Making Test, for education as well, by using normative data (means and standard deviations). Neuropsychological testing was conducted by a neuropsychologist or briefed study nurses, physicians, or technicians. The completed forms were sent to the Department of Neurology and Neuropsychology at the University Medical Center Regensburg for core laboratory analysis.
Core Laboratory Analysis and Clinical Follow-up
Patient data (clinical data, microembolic signal transcranial Doppler US data, cerebral MRI findings, and neuropsychological testing results) were collected by each center and sent to the Department of Neurology at the University of Regensburg for the core laboratory analysis. Offline analyses of recorded microembolic signal transcranial Doppler US data and MRI data were performed as described above by experienced neurologists. Neuropsychological testing data were analyzed with a computerized software algorithm by an experienced neuropsychologist, who was blinded to the microembolic signal transcranial Doppler US and MRI data. In 2016, all study patients were contacted by telephone to complete an applicable questionnaire, including occurrence of symptomatic neurologic events, reablation procedures, and the status of oral anticoagulation.
Statistical Analysis
Descriptive data are presented as a mean 6 standard deviation and as percentages. For the investigation of correlations, the nonparametric Spearman correlation coefficient was determined. P < .05 was considered statistically significant. Additionally, scatter plots were generated as graphical displays, illustrating the microembolic signals (total, gaseous, solid, and equivocal) or thromboembolic shower count on the y-axis and the value for new DWI lesions on the x-axis when illustrating the impact of microembolic signals on the occurrence of new DWI lesions. The pre-post differences in the z scores were displayed on the y-axis and the total microembolic signal/thromboembolic shower count on the xaxis when illustrating the impact of microembolic signals on neuropsychological testing.
Results
Patient Characteristics
Sixty-five patients with symptomatic atrial fibrillation were treated with pulmonary vein isolation at the 3 study centers between July 2011 and November 2012; however, for this analysis, only 41 patients (30 male patients and 11 female patients) were eligible for analysis. Twenty-four patients were excluded because complete follow-up data were not available ( Figure 1 and Table 1 ).
Ablation Procedure
Pulmonary vein isolation was performed using phased RF ablation in 23 patients, irrigated RF ablation in 13 patients, and cryoablation in 5 patients. The mean lengths of the procedures were 164 6 70 minutes in total, 174 6 77 minutes in the phased RF (pulmonary vein ablation catheter) group, 149 6 45 minutes in the irrigated RF group, and 169 6 82 minutes in the cryoablation group; the mean fluoroscopy times were 34 6 18, 25 6 10, and 20 6 7 minutes, respectively. Complete isolation could be achieved in all pulmonary veins. No additional left atrial ablation was performed.
Microembolic Signal Count and Differentiation
Impact of the Microembolic Signal/ Thromboembolic Shower Count on New DWI Lesions Fluid-attenuated inversion recovery MRI studies revealed preexisting cerebral lesions in 32 patients (78%). Magnetic resonance imaging using DWI and apparent diffusion coefficient sequences ruled out the presence of acute cerebral ischemia before the ablation procedures. A total of 45 new lesions were detected by DWI-MRI in 20 (49%) patients 1 day after the ablation procedure. No additional DWI lesions were found 1 month after the ablation procedure. The calculated correlation coefficient showed no correlation between the occurrence of microembolic signals (subdivided into total, gaseous, solid, and equivocal) and the occurrence of new DWI lesions (Figure 2) . Also, thromboembolic showers did not correlate with new DWI lesions (Figure 3) .
Impact of the Microembolic Signal Count on Neuropsychological Testing
The nonparametric Spearman correlation coefficient showed no correlation between the total number of microembolic signals or thromboembolic showers on the neuropsychological capability. The absence of a correlation was apparent 1 day after pulmonary vein isolation but also in the 1-month follow-up (Figure 4 ).
Microembolic Signal Count and Clinical Long-term Follow-up
No clinical stroke during acute the hospital stay after pulmonary vein isolation was documented; this finding also applied to the patient with the highest (n 5 8317) 
Discussion
To our knowledge, this work is the first multicenter study to correlate the impact of the microembolic signal count during pulmonary vein isolation on the (sub)clinical outcome represented by the occurrence of new DWI lesions, changes in the neuropsychological capability, and the occurrence of symptomatic cerebral events during long-term follow-up after a left atrial catheter ablation for atrial fibrillation. Our results demonstrate the following findings: (1) There is no correlation between the microembolic signal/thromboembolic shower count during the procedure and the occurrence of new DWI lesions after pulmonary vein isolation. This finding was also the case when analyzing subgroups of microembolic signals (solid, gaseous, and equivocal). (2) There is no correlation between the microembolic signal/thromboembolic shower count during the procedure and the neuropsychological capability measured 1 day and 1 month after pulmonary vein isolation. (3) On of 39 patients had a single transient ischemic attack during long-term follow-up. This patient had a relatively low microembolic signal count but the highest thromboembolic shower count within the study population. Patients with a high microembolic signal count showed no clinical overt neurologic deficit during long-term follow-up.
Pulmonary vein isolation is a milestone in the treatment of paroxysmal and persistent atrial fibrillation. However, it may be complicated by clinical stroke or asymptomatic silent cerebral embolism detected by DWI-MRI. [1] [2] [3] [4] This factor raises the question of whether there is availability of online tests with the ability to detect potential brain injury during the ablation procedure. The microembolic signal count measured by intraprocedural transcranial Doppler US has evolved as a risk stratification tool for future cerebral ischemic events in different diseases (ie, atherosclerotic stenosis of the internal carotid artery). 8, [26] [27] [28] In addition, the microembolic signal count also was considered a surrogate for stroke risk during cardiac procedures such as percutaneous left heart catheterization, 10 ,29 cardiosurgery, 30, 31 and recently, left atrial catheter ablation for atrial fibrillation. [12] [13] [14] [15] [16] However, the effects of the microembolic signal count on the clinical outcome remain controversial 10, [29] [30] [31] and, particularly during pulmonary vein isolation, are not well evaluated.
According to prior studies indicating microembolic signals as a risk factor for cerebral injury in different cardiac procedures, microembolic signal detection was equated with a higher risk of ischemic cerebral events during left atrial ablation procedures as well. As a consequence, different ablation strategies and catheter settings during pulmonary vein isolation have been evaluated, aiming at a reduction of microembolic signals and thus hopefully also a reduction in cerebral ischemic events. 5, [12] [13] [14] [15] [16] However, it is unclear whether prior study results indicating a correlation between the microembolic signal count and neurocognitive decline (ie, during percutaneous coronary interventions) can be transferred to a pulmonary vein isolation procedure. For example, Lund et al 10 found new cerebral lesions associated with a higher number of solid emboli during percutaneous coronary interventions. Interestingly, although such a correlation was found, the maximum microembolic signal count and the percentage of solid emboli (7.9% versus 22%) were much lower than in our study, indicating that divergent procedural (ie, manipulation with a guide wire causing mechanical force on atherosclerotic plaques close to cerebral arteries and no preprocedural oral anticoagulation) or pathophysiologic (ie, consistency of embolus formation) aspects may be responsible for the positive correlation between the microembolic signal count and new DWI lesions. Thus, the impact of microembolic signals during percutaneous coronary interventions (or other cardiac procedures) must not match the impact of microembolic signals during pulmonary vein isolation.
Nevertheless, there are also some data concerning microembolic signals and the neurologic outcome after pulmonary vein isolation. Kilicaslan et al 11 were the first to describe an association between the microembolic signal count and overt periprocedural neurologic complications, giving a complication rate of 36% in patients with more than 3000 microembolic signals during ablation. This finding was in contrast to our results, as we did not find such a correlation, even in patients with more than 8000 microembolic signals or after a follow-up period of 49 6 4 months. Again, this difference also may have been due to differing procedural aspects, such as continuous oral anticoagulation without bridging with heparin when using warfarin, the use of a 4-mm-tip irrigated RF catheter, and abandonment of protamine after the ablation procedure in our study. A study by Kochh€ auser et al 19 found factors such as age and the number of microembolic signals to correlate with subtle deterioration in a subgroup of their von Bary et al-Microembolic Signal Burden During Catheter Ablation for Atrial Fibrillation neuropsychological test battery. Remarkably, neuropsychological testing was conducted 6 months after ablation, raising the question of whether microembolic signals have a small but longer-lasting effect on higher cortical function, thus being apparent in neuropsychological testing after a longer period. As mentioned above, we found at least no evidence of overt neurologic impairment during a 1-month follow-up even in patients with very high microembolic signal counts.
Apart from the neurocognitive decline, our study also found no correlation between microembolic signals and the silent cerebral embolism burden. This finding was remarkable, as one would expect a high incidence of new silent cerebral embolisms in cases with a relevant microembolic signal burden. One possible explanation concerning this phenomenon is that, under certain circumstances, a measurable microembolic impact may be counterbalanced by cerebral autolytic function. Again, the autolytic capacity might be influenced by variables such as the extent of preexisting cerebral damage (white matter lesions), the mode of oral/nonoral anticoagulation therapy, composition of microembolic signals, location of hits related to the burden (microembolic cluster), and size of microembolic signals.
Taken together, in our study, no correlation between microembolic signals/thromboembolic showers and cerebral injury after left atrial catheter ablation was detected. Whereas DWI-MRI can be considered the reference standard for early detection of cerebral ischemic injury, the microembolic signal count by transcranial Doppler US alone may not be a sufficient marker for assessing subsequent neurologic damage. Procedural or individual factors such as selection of the catheter system and lack of autolytic function of the brain may add to a measurable brain injury.
This study had several limitations: (1) We included only patients without prior stroke and a relatively low preexisting neurovascular burden, as shown by fluidattenuated inversion recovery MRI, thus presenting a population with prior hypertension as the main risk factor and no cardioembolic stroke despite atrial fibrillation. (2) Evaluation of large numbers of microembolic signals during offline assessments is a challenge also for an expert. However, the true impact on neurologic function and the brain structure of specific microembolic signals still needs to be determined. (3) Neuropsychological testing was performed 1 day and 1 month after the ablation procedure. Thus, potential changes in neurocognitive function at a later date were not captured. (4) Different anticoagulation regimens (warfarin without bridging versus dabigatran with bridging) were used during the study. This factor may have potentially influenced the occurrence of microembolic signals and new DWI lesions. However, in all patients, an activated clotting time of greater than 300 seconds was mandatory, ensuring sufficient anticoagulation during the procedure and thus during microembolic signal recording. (5) For technical reasons, only unilateral insonation during transcranial Doppler recording was feasible in 7 patients. Therefore, we investigated the relationship between individual measurements and sides upfront. This investigation showed clearly that there is no consistent trend between individual patient sides, and there is no valid conversion factor. Thus, to replace contralateral values, we decided to apply the best-case replacement strategy on a patient level: ie, setting missing values to 0. However, on the basis of high variation in the microembolic signal values, we do not expect a relevant impact on the overall results based on this replacement strategy. (6) Finally, there might be a side-related impact of recorded microembolic signals on MRI findings. Further studies on microembolic signals in association with ablation procedures are necessary to study the embolic outflow into the aortic arch with its brain-supplying arteries to further understand side-to-side differences of new DWI lesions.
In conclusion, in this study, we found no correlation between the intraprocedural microembolic signal/ thromboembolic shower count and the occurrence of new DWI-detected cerebral lesions or the neuropsychological capability after left atrial catheter ablation. During long-term follow-up, even patients with a high microembolic signal count showed no clinical overt neurologic deficit. Thus, not only the microembolic signal count but also procedural/individual factors may contribute to commensurable clinical damage, which may challenge this method as a valid biomarker during pulmonary vein isolation.
